Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aristeromycin SCHEMBL10353292 | 1.00 | AHCY (1.00) | AHCYADORA2B | |
| Aristeromycin SCHEMBL12280589 | 1.00 | AHCY (1.00) | AHCYADORA2B | |
| Aristeromycin SCHEMBL10353291 | 1.00 | AHCY (1.00) | AHCYADORA2B | |
| Aristeromycin SCHEMBL14515457 | 1.00 | AHCY (1.00) | AHCYADORA2B | |
| Aristeromycin SCHEMBL29695815 | 1.00 | AHCY (1.00) | AHCYADORA2B | |
| Aristeromycin SCHEMBL12173988 | 1.00 | AHCY (1.00) | AHCYADORA2B | |
| Aristeromycin SCHEMBL7534801 | 1.00 | AHCY (1.00) | AHCYADORA2B | |
| Aristeromycin SCHEMBL9820408 | 1.00 | AHCY (1.00) | AHCYADORA2B | |
| Aristeromycin SCHEMBL12157242 | 1.00 | AHCY (1.00) | AHCYADORA2B | |
| SCHEMBL15297972 | 0.99 | AHCY (0.97) | AHCYADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 598 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| EP-4714452-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | Gilead Sciences, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2024-05-02 | — | — | US | claimed |
| US-11660307-B2 | Methods for treating SARS CoV-2 infections | GILEAD SCIENCES, INC. (US) | 2023-05-30 | — | — | US | claimed |
| EP-4045504-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | Ai-biopharma (FR) | 2022-08-24 | — | — | EP | claimed |
| WO-2022160323-A1 | APPLICATION OF NUCLEOSIDE ANALOGUE IN PREPARATION OF DRUGS FOR PREVENTING OR TREATING GASTROINTESTINAL DISEASES | 兰州大学 | 2022-08-04 | — | — | WO | claimed |
| CN-114533739-A | Application of nucleoside analogue in preparing medicine for preventing or treating gastrointestinal tract diseases | 兰州大学 | 2022-05-27 | — | — | CN | claimed |
| US-20210299143-A1 | USE OF ANTAGONISTS TO THE NUCLEAR STEROID RECEPTOR TO INHIBIT CORONAVIRUSES | Spectral Analytics, Inc. (US) | 2021-09-30 | — | — | US | claimed |
| WO-2021074443-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2021-04-22 | — | — | WO | claimed |
| US-20160250247-A1 | VITAMIN B6 DERIVATIVES OF NUCLEOTIDES, ACYCLONUCLEOTIDES AND ACYCLONUCLEOSIDE PHOSPHONATES | MBC PHARMA, INC. | 2016-09-01 | — | — | US | claimed |
| WO-1996020010-A1 | COMBINATION FOR REDUCING ANTIMICROBIAL RESISTANCE USING A METHYLATION INHIBITOR IN COMBINATION WITH AN ANTIBIOTIC | ORIDIGM CORPORATION (US) | 1996-07-04 | — | — | WO | claimed |
| EP-0334361-B1 | Novel acetylenic, cyano and allenic aristeromycin/adenosine derivatives | MERRELL DOW PHARMA (US) | 1995-04-19 | — | — | EP | claimed |
| CN-1023804-C | Novel acetylenic, cyano and allenic aristeromycin/adenosine derivatives | MERRELL DOW PHARMA (US) | 1994-02-16 | — | — | CN | claimed |
| CN-1023561-C | Process for preparing cryptoclindamycin/adenosine derivatives | MERRELL DOW PHARMA (US) | 1994-01-19 | — | — | CN | claimed |
| CN-1036579-A | Novel acetylenic, cyano group and allenic aristeromycin element/adenosine derivative | MERRELL DOW PHARMA (US) | 1989-10-25 | — | — | CN | claimed |
| EP-0334361-A2 | Novel acetylenic, cyano and allenic aristeromycin/adenosine derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-09-27 | — | — | EP | claimed |
| CN-1033632-A | NOVEL ARISTEROMYCIN/ADENOSINE DERIVATIVES | MERRELL DOW PHARMA (US) | 1989-07-05 | — | — | CN | claimed |
| EP-0304889-A2 | Novel aristeromycin/adenosine derivatives | MERRELL PHARMACEUTICALS INC. (US) | 1989-03-01 | — | — | EP | claimed |
| US-4740598-A | Conversion of aristeromycin into cyclaradine | SCHERING CORPORATION (US) | 1988-04-26 | — | — | US | claimed |
| EP-0246605-A2 | Conversion of aristeromycin into cyclaradine | SCHERING CORPORATION (US) | 1987-11-25 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | HAVCR2, NR1H4, NR1H3 | AHCY 3684/4885ADORA2B 2265/4885 |
| US-20160250247-A1 | VITAMIN B6 DERIVATIVES OF NUCLEOTIDES, ACYCLONUCLEOTIDES AND ACYCLONUCLEOSIDE PHOSPHONATES | PNPO, PNP, PPA1 | AHCY 249/4885ADORA2B 17/4885 |
| US-11660307-B2 | Methods for treating SARS CoV-2 infections | ACE2, ACE, PNP | AHCY 921/4885ADORA2B 836/4885 |
| US-20210299143-A1 | USE OF ANTAGONISTS TO THE NUCLEAR STEROID RECEPTOR TO INHIBIT CORONAVIRUSES | NCOA1, NCOA2, NCOA3 | AHCY 3060/4885ADORA2B 3923/4885 |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | SLC10A1, HAVCR2, HDGF | AHCY 4462/4885ADORA2B 4584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.